JPRN-jRCT2080221700终止2 期
A Randomized Phase 2 Non-Comparative Study Of The Efficacy Of PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer(B1271004)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 252
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- Female
入选标准
- •Recurrent endometrial carcinoma
- •- Disease progression following one or two lines of prior treatment with platinum containing chemotherapy
- •- Tumor tissue available at time of screening for PI3K analysis
- •- Adequate glucose control, bone marrow, kidney, liver, and heart function
排除标准
- •- More than 2 prior cytotoxic chemo regimens for endometrial carcinoma
- •- Prior therapy with an agent known to be a PI3K, and or mTOR and or AKT inhibitor
- •- Active brain metastases
研究者
相似试验
进行中（未招募）
不适用
Phase 2 comparative study of two investigational agents, PF04681502 and PF05212384 respectively, in women with advanced tumour of the uterus.RECURRENT ENDOMETRIAL CANCERMedDRA version: 14.0Level: PTClassification code 10014736Term: Endometrial cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-003062-32-SKPfizer Inc., 235 East 42nd Street, New York, NY 10017252
进行中（未招募）
不适用
Phase 2 comparative study of two investigational agents, PF04681502 and PF05212384 respectively, in women with advanced tumour of the uterus.RECURRENT ENDOMETRIAL CANCERMedDRA version: 14.1Level: PTClassification code 10014736Term: Endometrial cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-003062-32-DEPfizer Inc., 235 East 42nd Street, New York, NY 10017 US252
进行中（未招募）
1 期
Phase 2 comparative study of two investigational agents, PF04681502 and PF05212384 respectively, in women with advanced tumour of the uterus.EUCTR2011-003062-32-PLPfizer Inc., 235 East 42nd Street, New York, NY 10017252
进行中（未招募）
1 期
Phase 2 comparative study of two investigational agents, PF04681502 and PF05212384 respectively, in women with advanced tumour of the uterus.RECURRENT ENDOMETRIAL CANCERMedDRA version: 15.0 Level: PT Classification code 10014736 Term: Endometrial cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-003062-32-GBPfizer Inc., 235 East 42nd Street, New York, NY 1001767
进行中（未招募）
1 期
Phase 2 comparative study of two investigational agents, PF04681502 and PF05212384 respectively, in women with advanced tumour of the uterus.EUCTR2011-003062-32-ESPFIZER S252